Nycomed/Altana Merger Reflects “Strategic” Pressures On Mid-Size Firms
This article was originally published in The Pink Sheet Daily
Executive Summary
European firms reach $5.4 bil. deal.
You may also be interested in...
Nycomed Seeks U.S. Partner To Promote Alvesco Asthma Inhaler And Intranasal Omnaris
FDA approved Alvesco to treat asthma in patients 12 and older Jan. 10, the Swiss pharma tells “The Pink Sheet” DAILY.
Nycomed Seeks U.S. Partner To Promote Alvesco Asthma Inhaler And Intranasal Omnaris
FDA approved Alvesco to treat asthma in patients 12 and older Jan. 10, the Swiss pharma tells “The Pink Sheet” DAILY.
Nycomed Strengthens Dermatology Franchise With Bradley Purchase
Swiss firm offers $20 per share for New Jersey specialty pharma in deal valued at around $346 million.